259 related articles for article (PubMed ID: 25665548)
1. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
[TBL] [Abstract][Full Text] [Related]
2. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
4. ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells.
Chen X; Chen L; Zhang R; Yi Y; Ma Y; Yan K; Jiang X; Wang X
Neurosci Lett; 2013 Mar; 537():44-9. PubMed ID: 23356982
[TBL] [Abstract][Full Text] [Related]
5. Correlation between glioblastoma stem-like cells and tumor vascularization.
He H; Niu CS; Li MW
Oncol Rep; 2012 Jan; 27(1):45-50. PubMed ID: 21971709
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
7. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
9. Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells.
Yamamuro S; Sano E; Okamoto Y; Ochiai Y; Ohta T; Ogino A; Natsume A; Wakabayashi T; Ueda T; Hara H; Nakayama T; Yoshino A; Katayama Y
Int J Oncol; 2015 Nov; 47(5):1647-54. PubMed ID: 26397698
[TBL] [Abstract][Full Text] [Related]
10. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
11. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
12. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.
Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH
OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679
[TBL] [Abstract][Full Text] [Related]
14. miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2.
Wu N; Xiao L; Zhao X; Zhao J; Wang J; Wang F; Cao S; Lin X
FEBS Lett; 2012 Nov; 586(21):3831-9. PubMed ID: 22999819
[TBL] [Abstract][Full Text] [Related]
15. [Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis].
Ping YF; Yao XH; Bian XW; Chen JH; Zhang R; Yi L; Zhou ZH
Zhonghua Bing Li Xue Za Zhi; 2007 Mar; 36(3):179-83. PubMed ID: 17535685
[TBL] [Abstract][Full Text] [Related]
16. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells.
Yu SP; Yang XJ; Zhang B; Ming HL; Chen C; Ren BC; Liu ZF; Liu B
Chin Med J (Engl); 2011 Sep; 124(17):2599-604. PubMed ID: 22040410
[TBL] [Abstract][Full Text] [Related]
17. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
18. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
19. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
20. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells.
Lin Y; Sun H; Dang Y; Li Z
Oncol Rep; 2018 Feb; 39(2):687-694. PubMed ID: 29251326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
